OBJECTIVES: To determine the value of the combined use of fetal fibronectin (fFN) testing and transvaginal ultrasound measurement of cervical length (CL) for prediction of preterm birth (PTB) in asymptomatic high-risk women. METHODS: One hundred and forty-seven asymptomatic women at high-risk of PTB were referred to specialist antenatal clinics and underwent CL and fFN testing over a 12-month period. Women had both tests undertaken between 22(+0) and 30(+0) weeks' gestation, on one or more occasions. RESULTS: In those who labored spontaneously (n = 132), positive fFN and CL ≤ 25 mm was associated with a 53% risk of PTB at < 37(+0) weeks' gestation, compared to a 10% risk in those with a negative fFN and CL > 25 mm. With a known CL, the addition of positive fFN yielded significant hazard ratios regardless of CL (CL > 25 mm-HR 2.78, CL ≤ 25 mm-HR 3.14, p < 0.05). The hazard ratios were insignificant when CL results were added to a known fFN. CONCLUSIONS: In high-risk asymptomatic women, fFN may be used as a primary screening tool with CL measurement being reserved for those with a positive fFN result. Further prospective studies are needed to confirm our findings.
OBJECTIVES: To determine the value of the combined use of fetal fibronectin (fFN) testing and transvaginal ultrasound measurement of cervical length (CL) for prediction of preterm birth (PTB) in asymptomatic high-risk women. METHODS: One hundred and forty-seven asymptomatic women at high-risk of PTB were referred to specialist antenatal clinics and underwent CL and fFN testing over a 12-month period. Women had both tests undertaken between 22(+0) and 30(+0) weeks' gestation, on one or more occasions. RESULTS: In those who labored spontaneously (n = 132), positive fFN and CL ≤ 25 mm was associated with a 53% risk of PTB at < 37(+0) weeks' gestation, compared to a 10% risk in those with a negative fFN and CL > 25 mm. With a known CL, the addition of positive fFN yielded significant hazard ratios regardless of CL (CL > 25 mm-HR 2.78, CL ≤ 25 mm-HR 3.14, p < 0.05). The hazard ratios were insignificant when CL results were added to a known fFN. CONCLUSIONS: In high-risk asymptomatic women, fFN may be used as a primary screening tool with CL measurement being reserved for those with a positive fFN result. Further prospective studies are needed to confirm our findings.
Authors: Seung Mi Lee; Roberto Romero; Jeong Woo Park; Sun Min Kim; Chan-Wook Park; Steven J Korzeniewski; Tinnakorn Chaiworapongsa; Bo Hyun Yoon Journal: J Matern Fetal Neonatal Med Date: 2012-04-25
Authors: M Sean Esplin; Michal A Elovitz; Jay D Iams; Corette B Parker; Ronald J Wapner; William A Grobman; Hyagriv N Simhan; Deborah A Wing; David M Haas; Robert M Silver; Matthew K Hoffman; Alan M Peaceman; Steve N Caritis; Samuel Parry; Pathik Wadhwa; Tatiana Foroud; Brian M Mercer; Shannon M Hunter; George R Saade; Uma M Reddy Journal: JAMA Date: 2017-03-14 Impact factor: 56.272
Authors: Gwen K Healey; William Alexander Macdonald; Stefan Grzybowski; Robert Nevin; Jude Kornelsen; William E Hogg Journal: Can Fam Physician Date: 2018-03 Impact factor: 3.275
Authors: Yujing J Heng; Stella Liong; Michael Permezel; Gregory E Rice; Megan K W Di Quinzio; Harry M Georgiou Journal: Front Physiol Date: 2015-05-13 Impact factor: 4.566
Authors: Lisa Story; Nigel A B Simpson; Anna L David; Zarko Alfirevic Z; Phillip R Bennett; Matthew Jolly; Andrew H Shennan Journal: Eur J Obstet Gynecol Reprod Biol X Date: 2019-04-21